Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing's syndrome. The setback cast doubt on CORT's pipeline strength and triggered a sharp re-evaluation by analysts. It underscores the market's sensitivity to regulatory developments in small-cap drug makers. Following today's plunge, Corcept stock is down 70% versus its year-to-date high in late March. What FDA setback means for Co ...